Storia in 2 fonti

Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with

Raccontata da

statnews.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mesi fa

Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with

originale

endpoints.news1 mesi fa

Merck partner Kelun outlines Phase 3 lung cancer success in China study

Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit could translate to Western patients.

Leggi questa versione → originale

Timeline cronologica

giovedì 21 maggio 2026·statnews.com
Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with
giovedì 21 maggio 2026·endpoints.news
Merck partner Kelun outlines Phase 3 lung cancer success in China study
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit…